ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Transplantation · J Heart Lung Transplant · 2026-11-03

EPPVDN consensus statement giving graded recommendations for children and young adults with a Fontan circulation and cardiovascular dysfunction, covering pulmonary vasodilators, pathway obstruction, lymphatics, heart failure and antithrombotics; many rest on expert opinion.

Guideline
Opotowsky et al. Treatment of children and young adults with a Fontan circulation and cardiovascular dysfunction. 2026 Consensus Statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AHA, AEPC, EACTS, ISACHD, ISHLT and PICS
Transplantation · J Heart Lung Transplant · 2026-11-03

2026 EPPVDN consensus statement on treating pulmonary hypertension in infants, children and young adults: 6 graded recommendation tables and 3 treatment algorithms covering risk assessment, drugs, transcatheter and surgical options, subgroups and low-income settings.

Guideline
Hansmann et al. Treatment of pulmonary hypertension in infants, children and young adults. 2026 consensus statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AHA, AEPC, EACTS, ESPR, PASCAR, PCS, and PICS
Transplantation · Clin Transplant · 2026-11-01

Systematic review of 5 observational studies (4 meta-analysed for mortality) in heart transplant recipients: aspirin vs no aspirin was associated with lower all-cause mortality (HR 0.31, 95% CI 0.15–0.67); no significant association with CAV-related outcomes (exploratory).

Meta-analysisn = 5 studies
Fournier et al. Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta-analysis
Transplantation · Transpl Int · 2026-10-20

Meta-analysis of 17 studies (511 recipients) of HCC beyond Milan downstaged before living donor liver transplant: in the primary cohort recurrence was 22.1% and 5-year survival 75.8%. Downstaging succeeded in 47.5%; evidence is retrospective, mostly Asian.

Meta-analysisn = 511
Jo et al. Post-transplant oncologic outcomes after locoregional downstaging before living donor liver transplantation for hepatocellular carcinoma beyond Milan criteria: a systematic review and meta-analysis of selected cohorts
Transplantation · Clin Transplant · 2026-10-01

Meta-analysis of 12 cohort studies (457 recipients) of solid organ donors with multidrug-resistant Gram-negative bacteria: pooled donor-derived infection rate 29%; 40% in high-risk, 0% in low-risk transplants. 90-day mortality 14% overall, 49% with infection.

Meta-analysisn = 457
Paraskevas et al. Risk of Donor-Derived Infections From Organ Donors Colonized or Infected With Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis
Transplantation · Clin Transplant · 2026-10-01

Secondary analysis of two RCTs in heart transplant recipients (SCHEDULE, n=83; NOCTET, n=75): replacing calcineurin inhibitors with everolimus, or reducing calcineurin inhibitor dose with everolimus, did not change left ventricular mass versus standard calcineurin inhibitors.

Secondary analysisn = 158
Murbraech et al. Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients-Results From Two Randomized Controlled Trials
Transplantation · Transpl Int · 2026-09-23

In an open-label RCT of 60 kidney transplant recipients (of 100 planned) with late active AMR and de novo DSA, adding bortezomib to standard care did not improve the 12-month composite endpoint (40.0% vs 33.3%; p=0.59) and raised serious adverse events (76.7% vs 46.7%).

RCTn = 60
Snanoudj et al. Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial
Transplantation · Transpl Int · 2026-09-21

Meta-analysis of 20 observational studies: in controlled DCD liver transplant, normothermic regional perfusion was linked to less ischaemic cholangiopathy than non-NRP (RR 0.16; 1.8% vs 12.7%), less graft loss and death, and no difference vs brain-death donors.

Meta-analysisn = 20 studies
Ramírez-Esteban et al. Normothermic regional perfusion in controlled donation after circulatory death liver transplantation: an updated systematic review and meta-analysis versus non-NRP and brain-death donors
Transplantation · J Heart Lung Transplant · 2026-09-05

ISHLT expert consensus statement on caregivers and social support for adults and children considered for or after heart or lung transplant or LVAD: recommends early caregiver engagement, tailored training, ongoing burden assessment and psychosocial, palliative and peer support.

Guideline
McIlvennan et al. Engagement of Social Support Systems in Patients Being Considered for and Following Advanced Heart and Lung Surgical Therapies: An ISHLT Expert Consensus Statement
Transplantation · Am J Transplant · 2026-08-22

Updated American Society of Transplantation guidelines on vaccination, travel and safe living for solid organ transplant candidates and recipients, adding COVID-19 and RSV vaccines and noting live-attenuated vaccines can be given to select young recipients.

Guideline
Kumar et al. Vaccination and safe living strategies for solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Transplantation · Bone Marrow Transplant · 2026-08-21

In a randomised pilot trial of 79 patients with AML or MDS having 8/8 HLA-matched donor transplants, ATG plus post-transplant cyclophosphamide gave similar 100-day survival to ATG alone (94.9% vs 95.0%, p>0.9); median neutrophil engraftment was slower (22 vs 19 days).

RCTn = 79
Walker et al. A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium
Transplantation · Transplant Cell Ther · 2026-08-18

ASTCT guideline (17-expert panel, GRADE) on BPDCN: allogeneic HCT recommended in CR1 or CR2; autologous HCT suggested for unfit patients without marrow involvement; HCT not recommended after primary induction failure or active relapsed-refractory disease.

Guideline
Kharfan-Dabaja et al. Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy
Transplantation · J Heart Lung Transplant · 2026-07-30

European paediatric consensus statement on sport and supervised exercise for children and young adults with pulmonary hypertension: reviews exercise physiology, evidence and safety, and gives first recommendations, including on eligibility for competitive sport.

Guideline
Dorobantu et al. Sports and supervised exercise programs for children and young adults with pulmonary hypertension. 2026 consensus statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by the Association for European Pediatric and Congenital Cardiology (AEPC)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.